Abstract
Two human immunodeficiency virus-infected patients who needed etoposide therapy to control exacerbations of Castleman disease received four infusions of rituximab. Clinical and virologic relapses with increased blood human herpesvirus-8 DNA levels occurred in both patients 4 and 24 weeks later and were associated with a worsening of Kaposi sarcoma.
Copyright (c) 2005 Wiley-Liss, Inc.
MeSH terms
-
Adult
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20 / blood
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / therapeutic use*
-
Castleman Disease / complications
-
Castleman Disease / drug therapy*
-
Castleman Disease / virology
-
DNA, Viral / blood
-
HIV Infections / complications*
-
HIV Infections / virology
-
Herpesvirus 8, Human / isolation & purification
-
Humans
-
Male
-
Middle Aged
-
Rituximab
-
Sarcoma, Kaposi / complications*
-
Sarcoma, Kaposi / virology
-
Treatment Failure
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
Antineoplastic Agents
-
DNA, Viral
-
Rituximab